Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 240

Sort by

Sort Order Select

Journal Articles

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Shuhong Hu, Yifei Liu, Xiang Zhang, Xiaoqi Wang, Yanting Li, Mengqian Chu, Jie Yin, Yanglan Fang, Changgeng Ruan, Li Zhu, Depei Wu, Yang Xu

Blood (2024) 144 (20): 2136–2148.

https://doi.org/10.1182/blood.2023023601

Published: 2024

Includes: Supplemental data

Journal Articles

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 2180.

https://doi.org/10.1182/blood-2024-200423

Published: 2024

Journal Articles

Clinical Characteristics and Treament Outcomes of 104 Cases of Extranodal NK/T-Cell Lymphoma Undergoing Primary Treatment in Novel Agents Era

Haiwen Huang, Mao Jin, Caixia Li, Zhengming Jin, Depei Wu

Blood (2024) 144 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2024-201884

Published: 2024

Journal Articles

Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP±R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis

Tao You, Jingxian Gu, Peng Xu, Jiebing Xiao, Huiru Cao, Wei Dai, Jie Bai, Peng Wang, Xiao Ma, Depei Wu, Haiwen Huang

Blood (2024) 144 (Supplement 1): 3113.

https://doi.org/10.1182/blood-2024-204404

Published: 2024

Journal Articles

In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Blood (2024) 144 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2024-202764

Published: 2024

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2024-207545

Published: 2024

Journal Articles

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

Yunju Ma, Qingya Cui, Chunxiu Yang, Wei Cui, Mengyun Li, Zheng Li, Haiping Dai, Liqing Kang, Lei Yu, Zaixiang Tang, Jianxin Fu, Min Jiang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 683.

https://doi.org/10.1182/blood-2024-209249

Published: 2024

Journal Articles

A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Xiaodong Mo, He Huang, Feng Chen, Yi Luo, Jia Chen, Erlie Jiang, Yicheng Zhang, Linghui Xia, Chengwei Luo Luo, Xinchuan Chen, Nainong Li, Ming Jiang, Sujun Gao, Dongqin Yang, Qingli Zuo, Yimin Chen, Li Yao, Pan Liang, Depei Wu

Blood (2024) 144 (Supplement 1): 99.

https://doi.org/10.1182/blood-2024-193191

Published: 2024

Journal Articles

The C553-C581 Disulfide of Human Factor XI Is Crucial for Its Activation and Is Targeted By Thiol Isomerase Pdir

Yuxin Zhang, Shuo Liu, Zhenzhen Zhao, Keyu Lv, Chao Fang, Yue Han, Juhong Wu, Depei Wu, Jingyu Zhang, Aizhen Yang, Yi Wu

Blood (2024) 144 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2024-204517

Published: 2024

Journal Articles

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Xiaoqian Chen, Wei Cui, Qingya Cui, Zheng Li, Sifan Chen, Mengyun Li, Xuekai Li, Juan Chen, Yan Yu, Xin Zhang, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 270.

https://doi.org/10.1182/blood-2024-209163

Published: 2024

Journal Articles

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Song Jin, Lingzhi Yan, Jingjing Shang, Weiqin Yao, Xiaolan Shi, Zhi Yan, Depei Wu

Blood (2024) 144 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2024-209260

Published: 2024

Journal Articles

Multicellular Derived S100A8/A9 Maintains Megakaryocytes in an Immature State in Immune Thrombocytopenia

Jiaqian Qi, Jie Yin, Meng Zhou, Haohao Han, Depei Wu, Yue Han

Blood (2024) 144 (Supplement 1): 1167.

https://doi.org/10.1182/blood-2024-192965

Published: 2024

Journal Articles

Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 399.

https://doi.org/10.1182/blood-2024-210100

Published: 2024

Journal Articles

Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations

Xueqing Dou, Suning Chen, Depei Wu

Blood (2024) 144 (Supplement 1): 222.

https://doi.org/10.1182/blood-2024-207264

Published: 2024

Journal Articles

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2024-198959

Published: 2024

Journal Articles

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Chengcheng Fu, Lingzhi Yan, Weiqin Yao, Jingjing Shang, Song Jin, Shuang Yan, Fang Tang, Ziling Zhu, Depei Wu, Ying Li, Nishanthan Rajakumaraswamy, Wei Zheng, Hua Jiang, Zhaohui Liao, Zonghai Li

Blood (2024) 144 (Supplement 1): 4843.

https://doi.org/10.1182/blood-2024-204401

Published: 2024

Journal Articles

Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich”Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Zihao Wang, Chong-Sheng Qian, Yan Qiu, Hai-xia Zhou, Mingzhu Xu, Li-Qing Kang, Ai-Ning Sun, Depei Wu, Lei Yu, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 4840.

https://doi.org/10.1182/blood-2024-204636

Published: 2024

Journal Articles

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Jia Yin, Qingya Cui, Haiping Dai, Zheng Li, Liqing Kang, Wei Cui, Xiaopeng Tian, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2024-207197

Published: 2024

Journal Articles

Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Kai-Wen Tan, Shanshan Pei, Miao Wang, Lan Dai, Hao Zhang, Chun-Yan Chen, Zhen-Qi Huang, Hai-Ping Dai, Ying Wang, Miao Miao, Yue Han, Xiaowen Tang, Huiying Qiu, Suning Chen, Aining Sun, Depei Wu, Zheng Li, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2024-204762

Published: 2024

Journal Articles

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Yue Zhou, Juan Chen, Qingya Cui, Haiping Dai, Zheng Li, Jia Yin, Wei Cui, Mengyun Li, Xuekai Li, Xin Zhang, Feiran Gong, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang

Blood (2024) 144 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2024-199119

Published: 2024

NARROW

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Clinical Characteristics and Treament Outcomes of 104 Cases of Extranodal NK/T-Cell Lymphoma Undergoing Primary Treatment in Novel Agents Era

Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP±R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis

In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness

A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

The C553-C581 Disulfide of Human Factor XI Is Crucial for Its Activation and Is Targeted By Thiol Isomerase Pdir

Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial

Interim Analysis of Dara VRD in the Treatment of TE-NDMM Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Multicellular Derived S100A8/A9 Maintains Megakaryocytes in an Immature State in Immune Thrombocytopenia

Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma

Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich”Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Unleashing the Power of CD19 CAR-T in Relapsed AML: Findings from a Prospective Single-Center Clinical Trial

Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only